BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 27400128)

  • 1. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors.
    Gordts PL; Nock R; Son NH; Ramms B; Lew I; Gonzales JC; Thacker BE; Basu D; Lee RG; Mullick AE; Graham MJ; Goldberg IJ; Crooke RM; Witztum JL; Esko JD
    J Clin Invest; 2016 Aug; 126(8):2855-66. PubMed ID: 27400128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice.
    Foley EM; Gordts PLSM; Stanford KI; Gonzales JC; Lawrence R; Stoddard N; Esko JD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2065-74. PubMed ID: 23846497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
    Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adaptor protein PID1 regulates receptor-dependent endocytosis of postprandial triglyceride-rich lipoproteins.
    Fischer AW; Albers K; Krott LM; Hoffzimmer B; Heine M; Schmale H; Scheja L; Gordts PLSM; Heeren J
    Mol Metab; 2018 Oct; 16():88-99. PubMed ID: 30100244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ApoC-III ASO promotes tissue LPL activity in the absence of apoE-mediated TRL clearance.
    Ramms B; Patel S; Nora C; Pessentheiner AR; Chang MW; Green CR; Golden GJ; Secrest P; Krauss RM; Metallo CM; Benner C; Alexander VJ; Witztum JL; Tsimikas S; Esko JD; Gordts PLSM
    J Lipid Res; 2019 Aug; 60(8):1379-1395. PubMed ID: 31092690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice.
    Aalto-Setälä K; Weinstock PH; Bisgaier CL; Wu L; Smith JD; Breslow JL
    J Lipid Res; 1996 Aug; 37(8):1802-11. PubMed ID: 8864964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The hypolipidemic effect of cilostazol can be mediated by regulation of hepatic low-density lipoprotein receptor-related protein 1 (LRP1) expression.
    Kim HJ; Moon JH; Kim HM; Yun MR; Jeon BH; Lee B; Kang ES; Lee HC; Cha BS
    Metabolism; 2014 Jan; 63(1):112-9. PubMed ID: 24139096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
    Wolska A; Lo L; Sviridov DO; Pourmousa M; Pryor M; Ghosh SS; Kakkar R; Davidson M; Wilson S; Pastor RW; Goldberg IJ; Basu D; Drake SK; Cougnoux A; Wu MJ; Neher SB; Freeman LA; Tang J; Amar M; Devalaraja M; Remaley AT
    Sci Transl Med; 2020 Jan; 12(528):. PubMed ID: 31996466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
    Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
    Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins.
    Huang Y; Liu XQ; Rall SC; Mahley RW
    J Biol Chem; 1998 Jul; 273(28):17483-90. PubMed ID: 9651338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance.
    Laatsch A; Merkel M; Talmud PJ; Grewal T; Beisiegel U; Heeren J
    Atherosclerosis; 2009 May; 204(1):105-11. PubMed ID: 18834984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC; Havekes LM
    Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice.
    Zsigmond E; Kobayashi K; Tzung KW; Li L; Fuke Y; Chan L
    Hum Gene Ther; 1997 Nov; 8(16):1921-33. PubMed ID: 9382958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of specific apolipoprotein C-III isoforms on the binding of triglyceride-rich lipoproteins to the lipolysis-stimulated receptor.
    Mann CJ; Troussard AA; Yen FT; Hannouche N; Najib J; Fruchart JC; Lotteau V; André P; Bihain BE
    J Biol Chem; 1997 Dec; 272(50):31348-54. PubMed ID: 9395464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-Density Lipoprotein Receptor-Dependent and Low-Density Lipoprotein Receptor-Independent Mechanisms of Cyclosporin A-Induced Dyslipidemia.
    Kockx M; Glaros E; Leung B; Ng TW; Berbée JF; Deswaerte V; Nawara D; Quinn C; Rye KA; Jessup W; Rensen PC; Meikle PJ; Kritharides L
    Arterioscler Thromb Vasc Biol; 2016 Jul; 36(7):1338-49. PubMed ID: 27150391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of plasma triglycerides in apolipoprotein C-II transgenic mice overexpressing lipoprotein lipase in muscle.
    Pulawa LK; Jensen DR; Coates A; Eckel RH
    J Lipid Res; 2007 Jan; 48(1):145-51. PubMed ID: 17018885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
    Oscarsson J; Hurt-Camejo E
    Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.